A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study

NCT00192608 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

40

Enrollment

OTHER_GOV

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: saquinavir 500 formulation
DRUG: cross-over arm

Sponsor

Kirby Institute

Collaborators

[object Object]